Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

DI-Leu16-IL2, an Anti-CD20-Interleukin-2 Immunocytokine, Is Safe and Active in Patients with Relapsed and Refractory B-Cell Lymphoma: A Report of Maximum Tolerated Dose, Optimal Biologic Dose, and Recommended Phase 2 Dose

Frederick Lansigan, MD, Ryotaro Nakamura, MD, Donald P. Quick, MD, Daniel Vlock, MD, Andrew Raubitschek, MD, Stephen D. Gillies, PhD, Veronika Bachanova, MD

Blood (2016) 128 (22): 620.

https://doi.org/10.1182/blood.V128.22.620.620

Published: 2016

Journal Articles

Immunologic and Clinical Responses To a CD20-Targeted Immunocytokine, DI-Leu16-IL2, In Relapsed Non-Hodgkin Lymphoma

Ryotaro Nakamura, Robert Chen, MD, Joycelynne Palmer, PhD, Karl Gaal, MD, Auayporn Nademanee, MD, Leslie Popplewell, MD, James E. Talmadge, PhD, Stephen Gillies, PhD, David Colcher, PhD, Stephen J. Forman, MD, Andrew Raubitschek, MD

Blood (2013) 122 (21): 1808.

https://doi.org/10.1182/blood.V122.21.1808.1808

Published: 2013

Journal Articles

Comparative Analysis of Autologous Hematopoietic Cell Transplantation with Radioimmunotherapy (RIT) Based Conditioning Versus Total Body Irradiation (TBI) for High-Risk Diffuse Large Cell Lymphoma (DLCL): Toxicity and Efficacy

Amrita Krishnan, M.D., Joycelynne Palmer, PhD, Auayporn Nademanee, M.D., Andrew Raubitschek, MD, Dave Yamauchi, Neil Martin Kogut, MD, Laura Federico, Nicole Tsai, Stephen Forman, M.D.

Blood (2010) 116 (21): 32.

https://doi.org/10.1182/blood.V116.21.32.32

Published: 2010

Journal Articles

Phase I Trial Results Testing Adoptively Transferred T Cells Expressing CD20-Specific Chimeric Antigen Receptors Containing CD28 and CD137 Costimulatory Domains In Patients with Mantle Cell Lymphoma and Indolent Lymphoma

Brian G. Till, MD, Michael C. Jensen, MD, Xiaojun Qian, Jinjuan Wang, Ajay K Gopal, MD, David G. Maloney, Catherine G. Lindgren, Yukang Lin, John M. Pagel, MD, PhD, Lihua E Budde, MD., PhD, Andrew Raubitschek, MD, Stephen Forman, Philip Greenberg, Stanley R. Riddell, MD, Oliver W. Press, MD, PhD

Blood (2010) 116 (21): 561.

https://doi.org/10.1182/blood.V116.21.561.561

Published: 2010

Journal Articles

Yttrium 90 Plus High Dose BEAM Conditioning with Autologous Stem Cell Transplantation (ASCT); Effects of Prior Rituximab and Outcome of Poor Risk Non Hodgkin Lymphoma (NHL).

Amrita Krishnan, MD, FACP, Andrew Raubitschek, MD, Auayporn P. Nademanee, MD, N. Kogut, MD, Leslie Popplewell, MD, Ni-Chun Tsai, Joycelynne Palmer, PhD, Jennifer Simpson, Laura Federico, Dave Yamauchi, MD, Stephen J. Forman, MD

Blood (2009) 114 (22): 2323.

https://doi.org/10.1182/blood.V114.22.2323.2323

Published: 2009

Journal Articles

Y90 Plus High Dose BEAM with Autologous Stem Cell Transplantation for Chemorefractory Non Hodgkin Lymphoma.

Amrita Krishnan, MD, FACP, Andrew Raubitschek, MD, Joycelynne Palmer, PHD, Auayporn P. Nademanee, MD, N. Kogut, MD, Dave Yamauchi, MD, Leslie Popplewell, MD, Laura Federico, Jennifer Simpson, Ni-Chun Tsai, Stephen J Forman, MD

Blood (2009) 114 (22): 3423.

https://doi.org/10.1182/blood.V114.22.3423.3423

Published: 2009

Journal Articles

90 .y-Ibritumomab Tiuxetan (Zevalin®) May Enhance Anti-Lymphoma Effect of Reduced-Intensity Fludarabine and Melphalan Regimen in Patients with Relapsed, Refractory B-Cell Non-Hodgkin Lymphoma (NHL) Undergoing Allogeneic Hematopoietic Cell Transplant (Allo-HCT).

Auayporn P. Nademanee, MD, Andrew Raubitschek, MD, Joycelynne Palmer, PHD, Dave Yamauchi, MD, Maria Delioukina, MD, Leslie Popplewell, MD, Firoozeh Sahebi, MD, Eileen Smith, MD, Anthony Stein, MD, Neil Kogut, MD, Margaret O'Donnell, MD, Stephen J Forman, MD

Blood (2009) 114 (22): 3357.

https://doi.org/10.1182/blood.V114.22.3357.3357

Published: 2009

Journal Articles

Updated Results of High-Dose Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan with High-Dose Etoposide (VP-16) and Cyclophosphamide (CY) Followed by Autologous Hematopoietic Cell Transplant (AHSCT) for Poor-Risk or Refractory B-Cell Non-Hodgkin’s Lymphoma.

Auayporn Nademanee, MD, Andrew Raubitschek, MD, Arturo Molina, MD, Joycelynne Palmer, Ph.D, Ni-Chun Tsai, MS, Amrita Krishnan, MD, Neil Kogut, MD, Stephen Forman, MD

Blood (2007) 110 (11): 1891.

https://doi.org/10.1182/blood.V110.11.1891.1891

Published: 2007

Journal Articles

A First-In-Human Clinical Trial of Adoptive Therapy Using CD19-Specific Chimeric Antigen Receptor Re-Directed T-Cells for Recurrent/Refractory Follicular Lymphoma.

Michael C. Jensen, MD, Leslie Popplewell, MD, David DiGiusto, PhD, Michael Kalos, PhD, Andrew Raubitschek, MD, Stephen J. Forman, MD

Blood (2007) 110 (11): 288.

https://doi.org/10.1182/blood.V110.11.288.288

Published: 2007

Journal Articles

Adoptive Cellular Therapy for Follicular Lymphoma Using Genetically-Modified Autologous CD20-Specific T Cells.

Brian G. Till, MD, Michael C. Jensen, MD, Jinjuan Wang, MD, Eric Y. Chen, MD, PhD, Scott James, PhD, Andrew Raubitschek, MD, Stephen J. Forman, MD, Ajay K. Gopal, MD, John M. Pagel, MD, PhD, Catherine G. Lindgren, Philip D. Greenberg, MD, Stanley R. Riddell, MD, Oliver W. Press, MD, PhD

Blood (2007) 110 (11): 499.

https://doi.org/10.1182/blood.V110.11.499.499

Published: 2007

Journal Articles

Preclinical Results of the Camptothecin-Polymer Conjugate IT-101 in Multiple Human Lymphoma Xenografts.

Tontanai Numbenjapon, MD, Jianyi Wang, MD, David Colcher, PhD, Thomas Schluep, ScD, Mark E. Davis, PhD, Julienne Duringer, BS, Stephen J. Forman, MD, Andrew Raubitschek, MD

Blood (2007) 110 (11): 1376.

https://doi.org/10.1182/blood.V110.11.1376.1376

Published: 2007

Journal Articles

The Impact of Incorporating Targeted Radioimmunotherapy (RIT) into Transplant Preparative Regimens on the Incidence of Therapy Related Myelodysplasia (t-MDS) or AML (t-AML) Following Autologous Stem Cell Transplant (ASCT) for Lymphoma.

Amrita Y. Krishnan, MD, Joycelynne M. Palmer, PhD, Smita C. Bhatia, MD, MPH, Auayporn Nademanee, MD, Stephen J. Forman, MD, Andrew Raubitschek, MD, Arturo M. Molina, MD, Henry Fung, MD, Peter Falk, MD, Marilyn J. Slovak, MD, Nicole Tsai, MS, Jennifer Simpson, BA, Ravi Bhatia, MD

Blood (2007) 110 (11): 1082.

https://doi.org/10.1182/blood.V110.11.1082.1082

Published: 2007

Journal Articles

A Comparison of Beam and Yttrium 90 Ibritumomab Tiuxetan (Zevalin®) in Addition to Beam (Z-BEAM) in Older Patients Undergoing Autologous Stem Cell Transplant (ASCT) for B-Cell Lymphomas: Impact of Radioimmunotherapy on Transplant Outcomes.

Amrita Y. Krishnan, MD, Auayporn Nademanee, MD, Andrew Raubitschek, MD, Henry C. Fung, MD, Arturo Molina, MD, David Yamauchi, MD, Peter M. Falk, MD, Ricardo Spielberger, MD, Joycelynne Palmer, PhD, Ni Chun Tsai, MS, MPH, Jeffrey Schriber, MD, Stephen J. Forman, MD

Blood (2006) 108 (11): 3043.

https://doi.org/10.1182/blood.V108.11.3043.3043

Published: 2006

Journal Articles

Preclinical Efficacy of Campthothecin-Polymer Conjugate (IT-101) in Human Burkitt Lymphoma Bearing Mice.

Tontanai Numbenjapon, MD, Jianyi Wang, MD, David Colcher, PhD, Thomas Schluep, ScD, Stephen J. Forman, MD, Andrew Raubitschek, MD

Blood (2006) 108 (11): 2489.

https://doi.org/10.1182/blood.V108.11.2489.2489

Published: 2006

Journal Articles

Combining Immunocytokine with Adoptive Immunotherapy To Treat B-Lineage Lymphomas.

Harjeet Singh, PhD, Lisa Marie A. Serrano, BS, Simon Olivares, BS, Michael Jensen, MD, George McNamara, PhD, David Colcher, MD, Andrew Raubitschek, MD, Laurence J.N. Cooper, MD, PhD

Blood (2005) 106 (11): 343.

https://doi.org/10.1182/blood.V106.11.343.343

Published: 2005

Journal Articles

New Transplant Strategies Utilizing Radioimmunotherapy (RIT) Based Regimens To Reduce Relapse in High Risk Mantle Cell Lymphoma (MCL).

Amrita Krishnan, MD, Andrew Raubitschek, MD, Stephen J. Forman, MD, Henry Fung, MD, Arturo Molina, MD, David Yamauchi, MD, Peter Falk, MD, Ricardo Spielberger, MD, Leslie Popplewell, MD, Roberto Rodriguez, MD, Pablo Parker, MD, Warren Chow, MD, Ryoto Nakamura, MD, Auayporn Nademanee, MD

Blood (2005) 106 (11): 681.

https://doi.org/10.1182/blood.V106.11.681.681

Published: 2005

Journal Articles

The Use of Reduced Intensity Allogeneic Stem Cell Transplantation (alloSCT) for Recurrence after Autologous Stem Cell Transplantation (ASCT) in Hodgkin’s Disease (HD).

Amrita Y. Krishnan, MD, Auayporn Nademanee, MD, Henry C. Fung, MD, Leslie Popplewell, MD, Roberto Rodriguez, MD, Zaid Al Kadhimi, MD, Mark Kirschbaum, MD, Neil Kogut, MD, Andrew Raubitschek, MD, Jeffrey Schriber, MD, Jasmine Zain, MD, Eileen Smith, MD, Nigel Cheng, Dajun Qian, PhD, Arturo Molina, MD, Stephen J. Forman, MD

Blood (2004) 104 (11): 5115.

https://doi.org/10.1182/blood.V104.11.5115.5115

Published: 2004

NARROW

DI-Leu16-IL2, an Anti-CD20-Interleukin-2 Immunocytokine, Is Safe and Active in Patients with Relapsed and Refractory B-Cell Lymphoma: A Report of Maximum Tolerated Dose, Optimal Biologic Dose, and Recommended Phase 2 Dose

Immunologic and Clinical Responses To a CD20-Targeted Immunocytokine, DI-Leu16-IL2, In Relapsed Non-Hodgkin Lymphoma

Comparative Analysis of Autologous Hematopoietic Cell Transplantation with Radioimmunotherapy (RIT) Based Conditioning Versus Total Body Irradiation (TBI) for High-Risk Diffuse Large Cell Lymphoma (DLCL): Toxicity and Efficacy

Phase I Trial Results Testing Adoptively Transferred T Cells Expressing CD20-Specific Chimeric Antigen Receptors Containing CD28 and CD137 Costimulatory Domains In Patients with Mantle Cell Lymphoma and Indolent Lymphoma

Yttrium 90 Plus High Dose BEAM Conditioning with Autologous Stem Cell Transplantation (ASCT); Effects of Prior Rituximab and Outcome of Poor Risk Non Hodgkin Lymphoma (NHL).

Y90 Plus High Dose BEAM with Autologous Stem Cell Transplantation for Chemorefractory Non Hodgkin Lymphoma.

90 .y-Ibritumomab Tiuxetan (Zevalin®) May Enhance Anti-Lymphoma Effect of Reduced-Intensity Fludarabine and Melphalan Regimen in Patients with Relapsed, Refractory B-Cell Non-Hodgkin Lymphoma (NHL) Undergoing Allogeneic Hematopoietic Cell Transplant (Allo-HCT).

Updated Results of High-Dose Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan with High-Dose Etoposide (VP-16) and Cyclophosphamide (CY) Followed by Autologous Hematopoietic Cell Transplant (AHSCT) for Poor-Risk or Refractory B-Cell Non-Hodgkin’s Lymphoma.

A First-In-Human Clinical Trial of Adoptive Therapy Using CD19-Specific Chimeric Antigen Receptor Re-Directed T-Cells for Recurrent/Refractory Follicular Lymphoma.

Adoptive Cellular Therapy for Follicular Lymphoma Using Genetically-Modified Autologous CD20-Specific T Cells.

Preclinical Results of the Camptothecin-Polymer Conjugate IT-101 in Multiple Human Lymphoma Xenografts.

The Impact of Incorporating Targeted Radioimmunotherapy (RIT) into Transplant Preparative Regimens on the Incidence of Therapy Related Myelodysplasia (t-MDS) or AML (t-AML) Following Autologous Stem Cell Transplant (ASCT) for Lymphoma.

A Comparison of Beam and Yttrium 90 Ibritumomab Tiuxetan (Zevalin®) in Addition to Beam (Z-BEAM) in Older Patients Undergoing Autologous Stem Cell Transplant (ASCT) for B-Cell Lymphomas: Impact of Radioimmunotherapy on Transplant Outcomes.

Preclinical Efficacy of Campthothecin-Polymer Conjugate (IT-101) in Human Burkitt Lymphoma Bearing Mice.

Combining Immunocytokine with Adoptive Immunotherapy To Treat B-Lineage Lymphomas.

New Transplant Strategies Utilizing Radioimmunotherapy (RIT) Based Regimens To Reduce Relapse in High Risk Mantle Cell Lymphoma (MCL).

The Use of Reduced Intensity Allogeneic Stem Cell Transplantation (alloSCT) for Recurrence after Autologous Stem Cell Transplantation (ASCT) in Hodgkin’s Disease (HD).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only